

Form 5500 Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Annual Return/Report of Employee Benefit Plan This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code). ▶ Complete all entries in accordance with the instructions to the Form 5500.	OMB Nos. 1210-0110 1210-0089 2021 This Form is Open to Public Inspection
---	---	---

Part I	Annual Report Identification Information
For calendar plan year 2021 or fiscal plan year beginning <u>01/01/2021</u> and ending <u>12/31/2021</u>	
A This return/report is for:	☐ a multiemployer plan ☐ a multiple-employer plan (Filers checking this box must attach a list of participating employer information in accordance with the form instructions.) ☒ a single-employer plan ☐ a DFE (specify) _____
B This return/report is:	☐ the first return/report ☐ the final return/report ☐ an amended return/report ☐ a short plan year return/report (less than 12 months)
C If the plan is a collectively-bargained plan, check here.	☐
D Check box if filing under:	☒ Form 5558 ☐ automatic extension ☐ the DFVC program ☐ special extension (enter description)
E If this is a retroactively adopted plan permitted by SECURE Act section 201, check here.	☐

Part II	Basic Plan Information—enter all requested information				
1a Name of plan <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN</u>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">1b Three-digit plan number (PN) ▶</td> <td style="width: 20%; text-align: center;"><u>001</u></td> </tr> <tr> <td colspan="2">1c Effective date of plan <u>01/01/2012</u></td> </tr> </table>	1b Three-digit plan number (PN) ▶	<u>001</u>	1c Effective date of plan <u>01/01/2012</u>	
1b Three-digit plan number (PN) ▶	<u>001</u>				
1c Effective date of plan <u>01/01/2012</u>					
2a Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.</u> <u>200 SUMMIT LAKE DRIVE</u> <u>VALHALLA, NY 10595-1356</u>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>2b Employer Identification Number (EIN) <u>45-1177477</u></td> </tr> <tr> <td>2c Plan Sponsor's telephone number <u>919-337-4402</u></td> </tr> <tr> <td>2d Business code (see instructions) <u>325410</u></td> </tr> </table>	2b Employer Identification Number (EIN) <u>45-1177477</u>	2c Plan Sponsor's telephone number <u>919-337-4402</u>	2d Business code (see instructions) <u>325410</u>	
2b Employer Identification Number (EIN) <u>45-1177477</u>					
2c Plan Sponsor's telephone number <u>919-337-4402</u>					
2d Business code (see instructions) <u>325410</u>					

Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

SIGN HERE	Filed with authorized/valid electronic signature.	10/17/2022	CAROLYN GORDON
	Signature of plan administrator	Date	Enter name of individual signing as plan administrator
SIGN HERE	Filed with authorized/valid electronic signature.	10/17/2022	CAROLYN GORDON
	Signature of employer/plan sponsor	Date	Enter name of individual signing as employer or plan sponsor
SIGN HERE			
	Signature of DFE	Date	Enter name of individual signing as DFE

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Form 5500 (2021)
v. 210624

3a Plan administrator's name and address ☒ Same as Plan Sponsor		3b Administrator's EIN	
		3c Administrator's telephone number	
4 If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: a Sponsor's name c Plan Name		4b EIN 4d PN	
5 Total number of participants at the beginning of the plan year		5	1317
6 Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines 6a(1) , 6a(2) , 6b , 6c , and 6d).			
a(1) Total number of active participants at the beginning of the plan year.....		6a(1)	1115
a(2) Total number of active participants at the end of the plan year		6a(2)	1354
b Retired or separated participants receiving benefits.....		6b	4
c Other retired or separated participants entitled to future benefits		6c	305
d Subtotal. Add lines 6a(2) , 6b , and 6c		6d	1663
e Deceased participants whose beneficiaries are receiving or are entitled to receive benefits.		6e	0
f Total. Add lines 6d and 6e		6f	1663
g Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item)		6g	1663
h Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested		6h	96
7 Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item).....		7	
8a If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristics Codes in the instructions: 2E 2F 2G 2J 2K 2R 2S 2T 3D 3H			
b If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristics Codes in the instructions:			
9a Plan funding arrangement (check all that apply) (1) ☒ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor		9b Plan benefit arrangement (check all that apply) (1) ☒ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor	
10 Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)			
a Pension Schedules (1) ☒ R (Retirement Plan Information) (2) ☐ MB (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary (3) ☐ SB (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary		b General Schedules (1) ☒ H (Financial Information) (2) ☐ I (Financial Information – Small Plan) (3) ☒ <u>1</u> A (Insurance Information) (4) ☒ C (Service Provider Information) (5) ☒ D (DFE/Participating Plan Information) (6) ☐ G (Financial Transaction Schedules)	

Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)

11a If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

If "Yes" is checked, complete lines 11b and 11c.

11b Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

11c Enter the Receipt Confirmation Code for the 2021 Form M-1 annual report. If the plan was not required to file the 2021 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code _____

SCHEDULE A (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Insurance Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500. ▶ Insurance companies are required to provide the information pursuant to ERISA section 103(a)(2).	OMB No. 1210-0110 2021 This Form is Open to Public Inspection
---	--	--

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021	
A Name of plan FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN	B Three-digit plan number (PN) ▶ 001
C Plan sponsor's name as shown on line 2a of Form 5500 FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.	D Employer Identification Number (EIN) 45-1177477

Part I	Information Concerning Insurance Contract Coverage, Fees, and Commissions	Provide information for each contract on a separate Schedule A. Individual contracts grouped as a unit in Parts II and III can be reported on a single Schedule A.
--------	---	--

1 Coverage Information:

(a) Name of insurance carrier
PRUDENTIAL RETIREMENT INSURANCE AND ANNUITY COMPANY

(b) EIN	(c) NAIC code	(d) Contract or identification number	(e) Approximate number of persons covered at end of policy or contract year	Policy or contract year	
				(f) From	(g) To
06-1050034	93629	031530	1663	01/01/2021	12/31/2021

2 Insurance fee and commission information. Enter the total fees and total commissions paid. List in line 3 the agents, brokers, and other persons in descending order of the amount paid.

(a) Total amount of commissions paid	(b) Total amount of fees paid
0	0

3 Persons receiving commissions and fees. (Complete as many entries as needed to report all persons).

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

(a) Name and address of the agent, broker, or other person to whom commissions or fees were paid

(b) Amount of sales and base commissions paid	Fees and other commissions paid		(e) Organization code
	(c) Amount	(d) Purpose	

Part II Investment and Annuity Contract Information

Where individual contracts are provided, the entire group of such individual contracts with each carrier may be treated as a unit for purposes of this report.

4	Current value of plan's interest under this contract in the general account at year end	4	0
5	Current value of plan's interest under this contract in separate accounts at year end.....	5	30515287

6 Contracts With Allocated Funds:**a** State the basis of premium rates ▶

b	Premiums paid to carrier	6b	
c	Premiums due but unpaid at the end of the year	6c	
d	If the carrier, service, or other organization incurred any specific costs in connection with the acquisition or retention of the contract or policy, enter amount. Specify nature of costs ▶	6d	

e Type of contract: (1) ☐ individual policies (2) ☐ group deferred annuity
(3) ☐ other (specify) ▶

f If contract purchased, in whole or in part, to distribute benefits from a terminating plan, check here ☐**7** Contracts With Unallocated Funds (Do not include portions of these contracts maintained in separate accounts)

a Type of contract: (1) ☐ deposit administration (2) ☐ immediate participation guarantee
(3) ☐ guaranteed investment (4) ☐ other ▶

b	Balance at the end of the previous year	7b	0
----------	---	-----------	----------

c	Additions: (1) Contributions deposited during the year	7c(1)		
	(2) Dividends and credits.....	7c(2)		
	(3) Interest credited during the year.....	7c(3)		
	(4) Transferred from separate account.....	7c(4)		
	(5) Other (specify below)	7c(5)		
	▶			

(6) Total additions	7c(6)	0
---------------------------	--------------	----------

d Total of balance and additions (add lines 7b and 7c(6))	7d	0
---	-----------	----------

e Deductions:			
(1) Disbursed from fund to pay benefits or purchase annuities during year	7e(1)		
(2) Administration charge made by carrier.....	7e(2)		
(3) Transferred to separate account.....	7e(3)		
(4) Other (specify below)	7e(4)		
▶			

(5) Total deductions	7e(5)	0
----------------------------	--------------	----------

f Balance at the end of the current year (subtract line 7e(5) from line 7d)	7f	0
---	-----------	----------

Part III Welfare Benefit Contract Information

If more than one contract covers the same group of employees of the same employer(s) or members of the same employee organizations(s), the information may be combined for reporting purposes if such contracts are experience-rated as a unit. Where contracts cover individual employees, the entire group of such individual contracts with each carrier may be treated as a unit for purposes of this report.

8 Benefit and contract type (check all applicable boxes)

- a** ☐ Health (other than dental or vision)
 b ☐ Dental
 c ☐ Vision
 d ☐ Life insurance
e ☐ Temporary disability (accident and sickness)
 f ☐ Long-term disability
 g ☐ Supplemental unemployment
 h ☐ Prescription drug
i ☐ Stop loss (large deductible)
 j ☐ HMO contract
 k ☐ PPO contract
 l ☐ Indemnity contract
m ☐ Other (specify) ▶

9 Experience-rated contracts:

a Premiums: (1) Amount received	9a(1)		
(2) Increase (decrease) in amount due but unpaid	9a(2)		
(3) Increase (decrease) in unearned premium reserve	9a(3)		
(4) Earned ((1) + (2) - (3))		9a(4)	
b Benefit charges (1) Claims paid	9b(1)		
(2) Increase (decrease) in claim reserves	9b(2)		
(3) Incurred claims (add (1) and (2))		9b(3)	
(4) Claims charged		9b(4)	
c Remainder of premium: (1) Retention charges (on an accrual basis) --			
(A) Commissions	9c(1)(A)		
(B) Administrative service or other fees	9c(1)(B)		
(C) Other specific acquisition costs	9c(1)(C)		
(D) Other expenses	9c(1)(D)		
(E) Taxes	9c(1)(E)		
(F) Charges for risks or other contingencies	9c(1)(F)		
(G) Other retention charges	9c(1)(G)		
(H) Total retention		9c(1)(H)	
(2) Dividends or retroactive rate refunds. (These amounts were ☐ paid in cash, or ☐ credited.)		9c(2)	
d Status of policyholder reserves at end of year: (1) Amount held to provide benefits after retirement		9d(1)	
(2) Claim reserves		9d(2)	
(3) Other reserves		9d(3)	
e Dividends or retroactive rate refunds due. (Do not include amount entered in line 9c(2).)		9e	

10 Nonexperience-rated contracts:

a Total premiums or subscription charges paid to carrier	10a	
b If the carrier, service, or other organization incurred any specific costs in connection with the acquisition or retention of the contract or policy, other than reported in Part I, line 2 above, report amount. Specify nature of costs.	10b	

Part IV Provision of Information

11 Did the insurance company fail to provide any information necessary to complete Schedule A? ☐ Yes ☒ No

12 If the answer to line 11 is "Yes," specify the information not provided. ▶

SCHEDULE C (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Service Provider Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110
		2021
		This Form is Open to Public Inspection.

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021		
A Name of plan FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN	B Three-digit plan number (PN) ▶	001
C Plan sponsor's name as shown on line 2a of Form 5500 FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.	D Employer Identification Number (EIN) 45-1177477	

Part I	Service Provider Information (see instructions)
---------------	--

You must complete this Part, in accordance with the instructions, to report the information required for **each person** who received, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of monetary value) in connection with services rendered to the plan or the person's position with the plan during the plan year. If a person received **only** eligible indirect compensation for which the plan received the required disclosures, you are required to answer line 1 but are not required to include that person when completing the remainder of this Part.

1 Information on Persons Receiving Only Eligible Indirect Compensation

- a** Check "Yes" or "No" to indicate whether you are excluding a person from the remainder of this Part because they received only eligible indirect compensation for which the plan received the required disclosures (see instructions for definitions and conditions)..... ☒ Yes ☐ No
- b** If you answered line 1a "Yes," enter the name and EIN or address of each person providing the required disclosures for the service providers who received only eligible indirect compensation. Complete as many entries as needed (see instructions).

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
PRUDENTIAL RETIREMENT INSURANCE AND
06-1050034

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

PRUDENTIAL RETIREMENT INSURANCE AND

06-1050034

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
13 15 37 50 64 65	NONE	83344	Yes ☒ No ☐	Yes ☒ No ☐	0	Yes ☒ No ☐

(a) Enter name and EIN or address (see instructions)

GETTRY MARCUS CPA, P.C.

13-3418879

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
10	NONE	23490	Yes ☐ No ☒	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

Part I Service Provider Information (continued)

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	

Part II Service Providers Who Fail or Refuse to Provide Information

4 Provide, to the extent possible, the following information for each service provider who failed or refused to provide the information necessary to complete this Schedule.

(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide

Part III Termination Information on Accountants and Enrolled Actuaries (see instructions)
(complete as many entries as needed)

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

SCHEDULE D (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration	DFE/Participating Plan Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection.
---	--	--

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021

A Name of plan <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN</u>	B Three-digit plan number (PN) <u>001</u>
C Plan or DFE sponsor's name as shown on line 2a of Form 5500 <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.</u>	D Employer Identification Number (EIN) <u>45-1177477</u>

Part I	Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs) (Complete as many entries as needed to report all interests in DFEs)
---------------	--

a Name of MTIA, CCT, PSA, or 103-12 IE: <u>CORE PLUS BOND / PGIM FD</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-299</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>5402970</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>INTERNATIONAL GROWTH / ARTISAN PART</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-259</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>3428289</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>T. ROWE PRICE LARGE CAP VALUE EQUIT</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-318</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>8529426</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>MID CAP GROWTH / ARTISAN PARTNERS F</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-185</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>4282275</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SMALL CAP GROWTH / TIMESSQUARE FUND</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-132</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>2995998</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SMALL CAP VALUE / INTEGRITY FUND</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-439</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>2995999</u>	
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>PRU DAY ONE IFX TARG BAL</u>			
b Name of sponsor of entity listed in (a): <u>PRUDENTIAL RETIREMENT INS.</u>			
c EIN-PN <u>06-1050034-697</u>	d Entity code <u>P</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>2880330</u>	

a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RET 2065 TRUST II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 82-6194314-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 269776
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE INCOME II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083967-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 1134461
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2015 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083984-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 1642221
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2020 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083982-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 1223681
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2025 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083980-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 7247646
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2030 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083978-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 7328508
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2035 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083976-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 16090560
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2040 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083974-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 12961050
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2045 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083972-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 5370932
a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2050 II		
b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY		
c EIN-PN 90-6083970-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 5472637

a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2055 II

b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY

c EIN-PN 27-6715091-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 5016674
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: VAN TGT RETIRE 2060 II

b Name of sponsor of entity listed in (a): VANGUARD FIDUCIARY TRUST COMPANY

c EIN-PN 45-3799419-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 3199243
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

Part II Information on Participating Plans (to be completed by DFEs)

(Complete as many entries as needed to report all participating plans)

a Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN

SCHEDULE H (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Financial Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection
--	--	--

For calendar plan year 2021 or fiscal plan year beginning <u>01/01/2021</u> and ending <u>12/31/2021</u>		
A Name of plan <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN</u>	B Three-digit plan number (PN) ►	<u>001</u>
C Plan sponsor's name as shown on line 2a of Form 5500 <u>FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.</u>	D Employer Identification Number (EIN) <u>45-1177477</u>	

Part I	Asset and Liability Statement
---------------	--------------------------------------

1 Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. **Round off amounts to the nearest dollar.** MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.

Assets		(a) Beginning of Year	(b) End of Year
a Total noninterest-bearing cash.....	1a	80	16
b Receivables (less allowance for doubtful accounts):			
(1) Employer contributions	1b(1)	276639	13803
(2) Participant contributions.....	1b(2)		
(3) Other	1b(3)		
c General investments:			
(1) Interest-bearing cash (include money market accounts & certificates of deposit)	1c(1)		
(2) U.S. Government securities	1c(2)		
(3) Corporate debt instruments (other than employer securities):			
(A) Preferred	1c(3)(A)		
(B) All other	1c(3)(B)		
(4) Corporate stocks (other than employer securities):			
(A) Preferred	1c(4)(A)		
(B) Common	1c(4)(B)		
(5) Partnership/joint venture interests	1c(5)		
(6) Real estate (other than employer real property)	1c(6)		
(7) Loans (other than to participants)	1c(7)		
(8) Participant loans	1c(8)	1539855	1853748
(9) Value of interest in common/collective trusts.....	1c(9)	49213140	66957389
(10) Value of interest in pooled separate accounts	1c(10)	24161658	30515287
(11) Value of interest in master trust investment accounts.....	1c(11)		
(12) Value of interest in 103-12 investment entities	1c(12)		
(13) Value of interest in registered investment companies (e.g., mutual funds)	1c(13)	32365768	40260406
(14) Value of funds held in insurance company general account (unallocated contracts).....	1c(14)		
(15) Other.....	1c(15)	12692458	13229254

		(a) Beginning of Year	(b) End of Year
1d	Employer-related investments:		
(1)	Employer securities.....	1d(1)	
(2)	Employer real property.....	1d(2)	
e	Buildings and other property used in plan operation	1e	
f	Total assets (add all amounts in lines 1a through 1e)	1f	120249598 152829903
Liabilities			
g	Benefit claims payable	1g	
h	Operating payables	1h	
i	Acquisition indebtedness.....	1i	
j	Other liabilities.....	1j	
k	Total liabilities (add all amounts in lines 1g through 1j)	1k	0 0
Net Assets			
l	Net assets (subtract line 1k from line 1f)	1l	120249598 152829903

Part II Income and Expense Statement

2 Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

		(a) Amount	(b) Total
Income			
a	Contributions:		
(1)	Received or receivable in cash from: (A) Employers	2a(1)(A)	11029745
	(B) Participants	2a(1)(B)	10673099
	(C) Others (including rollovers).....	2a(1)(C)	3690277
(2)	Noncash contributions.....	2a(2)	
(3)	Total contributions. Add lines 2a(1)(A) , (B) , (C) , and line 2a(2)	2a(3)	25393121
b	Earnings on investments:		
(1)	Interest:		
	(A) Interest-bearing cash (including money market accounts and certificates of deposit).....	2b(1)(A)	
	(B) U.S. Government securities	2b(1)(B)	
	(C) Corporate debt instruments	2b(1)(C)	
	(D) Loans (other than to participants)	2b(1)(D)	
	(E) Participant loans.....	2b(1)(E)	92426
	(F) Other	2b(1)(F)	299291
	(G) Total interest. Add lines 2b(1)(A) through (F)	2b(1)(G)	391717
(2)	Dividends: (A) Preferred stock.....	2b(2)(A)	
	(B) Common stock	2b(2)(B)	
	(C) Registered investment company shares (e.g. mutual funds).....	2b(2)(C)	430597
	(D) Total dividends. Add lines 2b(2)(A) , (B) , and (C)	2b(2)(D)	430597
(3)	Rents	2b(3)	
(4)	Net gain (loss) on sale of assets: (A) Aggregate proceeds	2b(4)(A)	
	(B) Aggregate carrying amount (see instructions).....	2b(4)(B)	
	(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result	2b(4)(C)	0
(5)	Unrealized appreciation (depreciation) of assets: (A) Real estate	2b(5)(A)	
	(B) Other	2b(5)(B)	-261439
	(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B)	2b(5)(C)	-261439

		(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts.....	2b(6)		7096226
(7) Net investment gain (loss) from pooled separate accounts.....	2b(7)		3954988
(8) Net investment gain (loss) from master trust investment accounts.....	2b(8)		
(9) Net investment gain (loss) from 103-12 investment entities.....	2b(9)		
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds).....	2b(10)		5397574
c Other income.....	2c		-20857
d Total income. Add all income amounts in column (b) and enter total.....	2d		42381927
Expenses			
e Benefit payment and payments to provide benefits:			
(1) Directly to participants or beneficiaries, including direct rollovers.....	2e(1)	9691313	
(2) To insurance carriers for the provision of benefits.....	2e(2)		
(3) Other.....	2e(3)		
(4) Total benefit payments. Add lines 2e(1) through (3).....	2e(4)		9691313
f Corrective distributions (see instructions).....	2f		
g Certain deemed distributions of participant loans (see instructions).....	2g		
h Interest expense.....	2h		
i Administrative expenses: (1) Professional fees.....	2i(1)		
(2) Contract administrator fees.....	2i(2)		
(3) Investment advisory and management fees.....	2i(3)		
(4) Other.....	2i(4)	110309	
(5) Total administrative expenses. Add lines 2i(1) through (4).....	2i(5)		110309
j Total expenses. Add all expense amounts in column (b) and enter total.....	2j		9801622
Net Income and Reconciliation			
k Net income (loss). Subtract line 2j from line 2d.....	2k		32580305
l Transfers of assets:			
(1) To this plan.....	2l(1)		
(2) From this plan.....	2l(2)		

Part III Accountant's Opinion

3 Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

a The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1) ☒ Unmodified (2) ☐ Qualified (3) ☐ Disclaimer (4) ☐ Adverse

b Check the appropriate box(es) to indicate whether the IQPA performed an ERISA section 103(a)(3)(C) audit. Check both boxes (1) and (2) if the audit was performed pursuant to both 29 CFR 2520.103-8 and 29 CFR 2520.103-12(d). Check box (3) if pursuant to neither.

(1) ☒ DOL Regulation 2520.103-8 (2) ☐ DOL Regulation 2520.103-12(d) (3) ☐ neither DOL Regulation 2520.103-8 nor DOL Regulation 2520.103-12(d).

c Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: GETTRY MARCUS CPA, P.C.

(2) EIN: 13-3418879

d The opinion of an independent qualified public accountant is **not attached** because:

(1) ☐ This form is filed for a CCT, PSA, or MTIA. (2) ☐ It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

Part IV Compliance Questions

4 CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l.

During the plan year:

a Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.).....

	Yes	No	Amount
4a		X	

	Yes	No	Amount
b Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)			
4b		X	
c Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)			
4c		X	
d Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)			
4d		X	
e Was this plan covered by a fidelity bond?	X		4500000
f Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?		X	
4f		X	
g Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?			
4g		X	
h Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?			
4h		X	
i Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)	X		
4i	X		
j Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked and see instructions for format requirements.)			
4j		X	
k Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?			
4k		X	
l Has the plan failed to provide any benefit when due under the plan?			
4l		X	
m If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)			
4m		X	
n If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.			
4n			

5a Has a resolution to terminate the plan been adopted during the plan year or any prior plan year? ☐ Yes ☒ No
If "Yes," enter the amount of any plan assets that reverted to the employer this year _____.

5b If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

5b(1) Name of plan(s)	5b(2) EIN(s)	5b(3) PN(s)

5c Was the plan a defined benefit plan covered under the PBGC insurance program at any time during this plan year? (See ERISA section 4021 and instructions.) ☐ Yes ☐ No ☐ Not determined
If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year _____.

SCHEDULE R (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Retirement Plan Information This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection.
---	--	---

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021

A Name of plan FUJIFILM DIOSYNTH BIOTECHNOLOGIES LONG TERM SAVINGS PLAN	B Three-digit plan number (PN) ► 001
C Plan sponsor's name as shown on line 2a of Form 5500 FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.	D Employer Identification Number (EIN) 45-1177477

Part I	Distributions
---------------	----------------------

All references to distributions relate only to payments of benefits during the plan year.

1 Total value of distributions paid in property other than in cash or the forms of property specified in the instructions.....	1	0
2 Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits): EIN(s): 22-1211670		
Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.		
3 Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year	3	

Part II	Funding Information (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)
----------------	---

4 Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)?	☐ Yes	☐ No	☐ N/A
If the plan is a defined benefit plan, go to line 8.			
5 If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. Date: Month _____ Day _____ Year _____ If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.			
6 a Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived)	6a		
b Enter the amount contributed by the employer to the plan for this plan year	6b		
c Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount)	6c		
If you completed line 6c, skip lines 8 and 9.			
7 Will the minimum funding amount reported on line 6c be met by the funding deadline?	☐ Yes	☐ No	☐ N/A
8 If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change?	☐ Yes	☐ No	☐ N/A

Part III	Amendments
-----------------	-------------------

9 If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box.....	☐ Increase	☐ Decrease	☐ Both	☐ No
--	-----------------------------------	-----------------------------------	-------------------------------	-----------------------------

Part IV	ESOPs (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.
----------------	---

10 Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan?	☐ Yes	☐ No
11 a Does the ESOP hold any preferred stock?	☐ Yes	☐ No
b If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.)	☐ Yes	☐ No
12 Does the ESOP hold any stock that is not readily tradable on an established securities market?	☐ Yes	☐ No

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Schedule R (Form 5500) 2021
v. 201209

Part V Additional Information for Multiemployer Defined Benefit Pension Plans

13 Enter the following information for each employer that contributed more than 5% of total contributions to the plan during the plan year (measured in dollars). See instructions. *Complete as many entries as needed to report all applicable employers.*

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

- 14** Enter the number of deferred vested and retired participants (inactive participants), as of the beginning of the plan year, whose contributing employer is no longer making contributions to the plan for:

a The current plan year. Check the box to indicate the counting method used to determine the number of inactive participants: ☐ last contributing employer ☐ alternative ☐ reasonable approximation (see instructions for required attachment).....

14a

b The plan year immediately preceding the current plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14b

c The second preceding plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14c

- 15** Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

a The corresponding number for the plan year immediately preceding the current plan year.....

15a

b The corresponding number for the second preceding plan year.....

15b

- 16** Information with respect to any employers who withdrew from the plan during the preceding plan year:

a Enter the number of employers who withdrew during the preceding plan year.....

16a

b If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers.....

16b

- 17** If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans

- 18** If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

- 19** If the total number of participants is 1,000 or more, complete lines (a) through (c)

a Enter the percentage of plan assets held as:

Stock: _____% Investment-Grade Debt: _____% High-Yield Debt: _____% Real Estate: _____% Other: _____%

b Provide the average duration of the combined investment-grade and high-yield debt:

☐ 0-3 years ☐ 3-6 years ☐ 6-9 years ☐ 9-12 years ☐ 12-15 years ☐ 15-18 years ☐ 18-21 years ☐ 21 years or more

c What duration measure was used to calculate line 19(b)?

☐ Effective duration ☐ Macaulay duration ☐ Modified duration ☐ Other (specify): _____

- 20 PBGC missed contribution reporting requirements.** If this is a multiemployer plan or a single-employer plan that is not covered by PBGC, skip line 20.

a Is the amount of unpaid minimum required contributions for all years from Schedule SB (Form 5500) line 40 greater than zero? ☐ Yes ☐ No

b If line 20a is "Yes," has PBGC been notified as required by ERISA sections 4043(c)(5) and/or 303(k)(4)? Check the applicable box:

☐ Yes.

☐ No. Reporting was waived under 29 CFR 4043.25(c)(2) because contributions equal to or exceeding the unpaid minimum required contribution were made by the 30th day after the due date.

☐ No. The 30-day period referenced in 29 CFR 4043.25(c)(2) has not yet ended, and the sponsor intends to make a contribution equal to or exceeding the unpaid minimum required contribution by the 30th day after the due date.

☐ No. Other. Provide explanation _____

**FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONG TERM SAVINGS PLAN
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2021 AND 2020**

GETTRYMARCUS



**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan**

Table of Contents

Years Ended December 31, 2021 and 2020

	<u>Page</u>
Independent Auditor's Report	1-4
Financial Statements:	
Statements of Net Assets Available for Benefits.....	5
Statements of Changes in Net Assets Available for Benefits	6
Notes to Financial Statements	7-15
Supplementary Information:	
Schedule of Assets (Held at End of Year).....	16-17

Independent Auditor's Report

To the Board of Trustees
FUJIFILM Diosynth Biotechnologies Long Term Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements (the "2021 financial statements").

Management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section:

- The amounts and disclosures in the accompanying 2021 financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying 2021 financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section of our report. We are required to be independent of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the 2021 Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments, administering the plan, and determining that the plan's transactions that are presented and disclosed in the financial statements are in conformity with the plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit of the 2021 Financial Statements section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if, there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

2021 Supplemental Schedule Required by ERISA

The supplemental Schedule of Assets (Held at End of Year) as of December 31, 2021 is presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedule, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedule that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, other than the information agreed to or derived from the certified investment information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated October 13, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Gettry Marcus CPA, P.C.

Gettry Marcus CPA, P.C.
Woodbury, New York
October 12, 2022

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Net Assets Available for Benefits
December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets		
Investments - at fair value	<u>\$ 150,962,352</u>	<u>\$ 118,433,104</u>
Receivables		
Employer contribution	13,803	276,639
Notes receivable from participants	<u>1,853,748</u>	<u>1,539,855</u>
Total receivables	<u>1,867,551</u>	<u>1,816,494</u>
Net assets available for benefits	<u><u>\$ 152,829,903</u></u>	<u><u>\$ 120,249,598</u></u>

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Changes in Net Assets Available for Benefits
Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions:		
Additions to net assets attributed to:		
Investment income		
Net appreciation in fair value of investments	\$ 16,166,492	\$ 14,916,657
Interest	299,291	316,304
Dividends	430,597	337,332
Net investment income	<u>16,896,380</u>	<u>15,570,293</u>
Interest income on notes receivable from participants	<u>92,426</u>	<u>83,663</u>
Contributions		
Employer	11,029,745	8,535,372
Participants	10,673,099	8,238,361
Rollovers	3,690,277	1,356,335
Total contributions	<u>25,393,121</u>	<u>18,130,068</u>
Total additions	<u>42,381,927</u>	<u>33,784,024</u>
Deductions:		
Deductions from net assets attributed to:		
Benefits paid to participants	9,691,313	7,612,713
Administrative expenses	110,309	93,665
Total deductions	<u>9,801,622</u>	<u>7,706,378</u>
Net increase	32,580,305	26,077,646
Net assets available for benefits		
Beginning of year	<u>120,249,598</u>	<u>94,171,952</u>
End of year	<u>\$ 152,829,903</u>	<u>\$ 120,249,598</u>

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020**

Note 1 – Description of Plan

The following description of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the “Plan”) provides only general information. Participants should refer to the Plan agreement for a more complete description of the Plan’s provisions.

General

The Plan is a defined contribution plan established effective January 1, 2012. Non-union, non-leased employees of FUJIFILM Diosynth Biotechnologies U.S.A., Inc. and FUJIFILM Diosynth Biotechnologies Texas LLC (collectively the “Employer” or “Company”) become eligible to participate upon commencement of employment and attaining the age of 21. The Plan was established as a prototype 401(k) defined contribution plan of Prudential Retirement Insurance and Annuity Company (“PRIAC”). Effective January 1, 2022, the Plan adopted the Prudential Non-Standardized Pre-Approved Profit Sharing/401(k) Plan (“Prudential Non-Standardized Plan”). The Plan is subject to the provisions of ERISA. The Board of Trustees of the Plan is responsible for oversight of the Plan. Management of the Company determines the appropriateness of the Plan’s investment offerings, monitors investment performance and reports to the Plan’s Board of Trustees.

Contributions

Each year, participants may contribute a pre-tax amount equal to not less than 1% and not more than 65%, of their pretax compensation, as defined in the Plan. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. The Plan accepts Roth Elective Deferrals made on behalf of participants. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans (“rollover”). Effective April 1, 2014, an employee is automatically enrolled in the Plan at 6% of eligible compensation, increasing by 1% a year up to a total of 15%, unless opting not to have any contributions or a different amount made on their behalf. Participants may also make a post-tax contribution in an amount equal to not less than 1% and not more than 10% of their compensation. The contributions are automatically invested in an age appropriate qualified default investment alternative fund until changed by the participant. Participants direct the investment of their contributions, the employer contributions and rollovers into various investment options offered by the Plan. The Company will make a safe harbor matching contribution for eligible employees who have made 401(k) contributions. The amount shall be equal to 100% of the first 6% of the eligible employees’ compensation that they contribute to the Plan. The Company also makes a non-elective contribution on behalf of each eligible employee. For employees hired before December 31, 2014, the non-elective contribution amount is equal to a percentage of his compensation, based on their years of vesting service and determined in accordance with the table below. For employees hired after December 31, 2014, the non-elective contribution is 3% of their eligible compensation, regardless of vesting service. During the year ended December 31, 2021, the Company accrued a true up contribution for 2021 of \$520,081, of which \$506,278 was funded with forfeitures, which was paid in August 2022. The Company has not finalized its true up contribution for 2020. The Company intends to use additional forfeitures from periods subsequent to December 31, 2021 to fund the 2020 true up contribution when finalized, and does not believe there will be a material effect to the financial statements. During the year ended December 31, 2020, the Company accrued a true up contribution for 2019 of \$276,639 which was paid in February 2021. During the years ended December 31, 2021 and 2020, the Company made contributions of \$11,029,745 and \$8,535,372, which includes non-elective contributions of \$4,450,533 and \$3,390,653, respectively. Contributions are subject to certain Internal Revenue Service (“IRS”) limitations as noted below:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

<u>Years of Vesting Service</u>	<u>Percentage of Compensation</u>
0 – 9	3%
10 – 19	4%
20 – 29	5%
30+	6%

Participant Accounts

Each participant's account is credited with the participant's contributions and Company matching contributions as well as an allocation of (a) the Company's non-elective contribution, (b) Plan earnings and losses and (c) Plan administrative expenses. Earnings (losses) and investment expenses are allocated by fund based on the ratio of a participant's account invested in a particular fund to all participants' investments in that fund. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants immediately vest 100 percent in their voluntary employee and safe harbor matching contributions plus actual earnings thereon. The balance of vesting in the participants' accounts is based on years of continuous service. However, if an active participant dies or becomes totally and permanently disabled prior to attaining the normal retirement age, the participant's account balance becomes 100 percent vested.

Participants' vested interest in their non-elective contributions shall be determined in accordance with the following schedule:

<u>Years of Vesting Service</u>	<u>Vested Interest</u>
Less than 3 years	0%
3 years or more	100%

Forfeited Accounts

Forfeitures of non-vested benefits are used to reduce Company contributions and plan expenses. Forfeited non-vested accounts totaled \$573,733 and \$295,132 at December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and 2020, \$23,490 and \$36,786, respectively, were used to offset Plan expenses (\$23,490 in 2021 and \$33,807 in 2020) and Company contributions (\$-0- in 2021 and \$2,979 in 2020). In August 2022, the Company accrued a true up contribution for 2021, of which \$506,278 was funded with forfeitures.

Payment of Benefits

On termination of service, including death, disability or retirement, a participant will receive a lump-sum amount or an installment payment equal to the value of the participant's vested interest in his or her account. The participant becomes 100% vested in his or her non-elective contribution upon death, disability or normal retirement. If the vested interest in the participant's account is \$5,000 or less, the account will be distributed in a single-sum payment or by direct rollover to an IRA or other eligible retirement plan, even if the participant does not consent. If the value is greater than \$5,000, distribution of the account cannot be made before normal retirement age without written consent. Distributions are subject to the applicable provisions of the Plan agreement.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

Notes Receivable from Participants

Participants may borrow from their fund accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50 percent of their vested account balance. Loans may not be made from the portion of accounts attributable to nonelective contributions. The loans are secured by the balance in the participant's account and bear interest at rates of 4.25% to 6.50%, which is commensurate with the local prevailing rates as determined by the Plan administrator. The loans must be repaid over a period not to exceed five years or ten years for the purchase of a primary residence. Principal and interest are paid ratably through payroll deductions. Effective July 1, 2017, a participant who pays off an existing plan loan may not apply for another plan loan during the six-month period following the payoff date of the prior plan loan. For the period of May 12, 2020 through December 31, 2020, a participant who pays off an existing plan loan may not apply for another plan loan during the seven-day period following the payoff date of the prior plan loan.

Coronavirus Aid, Relief and Economic Security Act

The Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was enacted on March 27, 2020. The CARES Act includes a number of relief provisions available to tax-qualified retirement plans. The provisions of the CARES Act may be effective and operationalized immediately (i.e., prior to amending the Plan document). The Plan has adopted certain measures included in the CARES Act as follows:

- Permit qualified individuals (as defined under the CARES Act) to request Coronavirus-Related Distributions up to \$100,000 from their vested portion of the Plan between January 1, 2020 and December 31, 2020.
- For loans taken within 180 days after the enactment of the CARES Act (i.e., March 27, 2020), permit qualified CARES Act individuals to take loans from their account up to the lesser of 100% of their vested account balance or \$100,000. In addition, permit any Plan loan repayment that comes due during the period March 27, 2020 through December 31, 2020 to be delayed for up to one year.
- Permit the delay of Required Minimum Distributions ("RMD") for a period of one year, with the delay applying to both 2019 distributions that were required to begin no later than April 1, 2020, and 2020 distributions, unless an employee elects to receive an RMD in 2020. Participants electing to receive a 2020 RMD amount are able to use the 60-day rollover option.

The timing and manner for formal plan amendments, as determined by the CARES Act, is for the Plan year ending December 31, 2022; however, the timing of the RMD provision was extended to the Plan year ending December 31, 2025.

Note 2 – Summary of Accounting Policies

Basis of Accounting

The financial statements of the Plan are prepared on the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and changes therein and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020**

Note 2 – Summary of Accounting Policies (continued)

Investment Valuation and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management of the Company determines the Plan's valuation policies utilizing information provided by the Plan's investment advisers, custodians and insurance company.

Purchases and sales of securities are recorded on a trade date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Interest income is recorded on an accrual basis. Related fees are recorded as administrative expenses and are expensed as incurred. No allowance for credit losses have been recorded as of December 31, 2021 and 2020. If a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded. Defaulted loans recorded as benefit payments amounted to \$97,987 and \$73,873 for the years ended December 31, 2021 and 2020, respectively.

Payments of Benefits

Benefits are recorded when paid by the Plan.

Administrative Expenses

The Plan's expenses are paid either by the Plan or the Company as provided by the Plan agreement. Certain administrative expenses of the Plan that are paid by the Plan are recorded as deductions in the accompanying statements of changes in net assets available for benefits. Expenses that are paid by the Company are excluded from these financial statements. Fees related to the administration of notes receivable from participants are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation of fair value of investments.

Accounting Standards Update ("ASU")

On August 28, 2018, FASB issued ASU 2018-13, Disclosure Framework—Changes to the Disclosure Requirement for Fair Value Measurement (Topic 820). The ASU, which applies to all entities (including defined contribution plans) removes, modifies and adds fair value and/or NAV related disclosures. The ASU is effective for years beginning after December 15, 2019. The Board of Trustees has determined that the adoption of ASU 2018-13 has no impact on its financial statements.

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.

The following information included in the accompanying financial statements and supplemental schedules was obtained from data that has been prepared and certified to as complete and accurate by PRIAC and Prudential Bank & Trust, F.S.B. ("PB&T"), (the trustees of the Plan), except for the stable value pooled separate account, which is only certified at its contract value at December 31, 2021 and 2020 of \$12,583,755 and \$11,763,491, respectively, for which the fair value adjustments of \$369,392 and \$630,831, respectively, and changes in adjustments from contract value to fair value of \$(261,439) and \$299,354, respectively, are not certified:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.
(continued)

	<u>2021</u>	<u>2020</u>
Investments:		
Pooled separate accounts	\$ 30,515,287	\$ 24,161,658
Mutual funds	40,260,422	32,365,848
Common/collective trusts	66,957,389	49,213,140
Stable value pooled separate account	12,583,755	11,763,491
Self-directed brokerage accounts	276,107	298,136
Total Investments	<u>\$ 150,592,960</u>	<u>\$ 117,802,273</u>
Notes receivable from participants	<u>\$ 1,853,748</u>	<u>\$ 1,539,855</u>
Interest income on notes receivable from participants	<u>\$ 92,426</u>	<u>\$ 83,663</u>
Investment income:		
Net appreciation in fair value of investments	\$ 16,427,931	\$ 14,617,303
Dividends	299,291	316,304
Interest	430,597	337,332
Total investment income	<u>\$ 17,157,819</u>	<u>\$ 15,270,939</u>

The assets of the Plan are invested at the direction of the participants in various investment funds at December 31, 2021 and 2020.

Note 4 – Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
---------	---

Level 2 Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
---------	---

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2021 and 2020.

Pooled separate accounts: Valued at fair value based on the current market values of the underlying assets of the fund.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Stable value pooled separate account: The stable value pooled separate account is not available in an exchange and active market, however, the fair value is determined based on the Plan's pro-rata share of the underlying investments in the pooled separate account. The underlying investments are principally comprised of investment grade: mortgage pools, corporate bonds and U.S. and foreign government bonds. Values are determined by quoted prices, market indexes, and bid and asked criteria.

Common/collective trusts: Valued at the daily closing price as reported by the fund. Common/collective trusts held by the Plan are composed of target retirement funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The target retirement funds held by the Plan are deemed to be actively traded.

Self-directed brokerage accounts: Consists of interest bearing cash, common stocks and mutual funds. The common stocks are valued at the closing price reported in the active market in which the individual securities are traded. The mutual funds are valued at the NAV of shares held by the Plan at year end. Cash is valued at fair value based on current market values of the underlying assets of the fund.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's investments at fair value at December 31, 2021 and 2020:

Investments at Fair Value at December 31, 2021

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 30,515,287	\$ -	\$ 30,515,287
Mutual funds	40,260,422	-	-	40,260,422
Common/collective trusts	-	66,957,389	-	66,957,389
Stable value pooled separate account	-	12,953,147	-	12,953,147
Self-directed brokerage accounts	276,107	-	-	276,107
Total investments at fair value	<u>\$ 40,536,529</u>	<u>\$ 110,425,823</u>	<u>\$ -</u>	<u>\$ 150,962,352</u>

Investments at Fair Value at December 31, 2020

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 24,161,658	\$ -	\$ 24,161,658
Mutual funds	32,365,848	-	-	32,365,848
Common/collective trusts	-	49,213,140	-	49,213,140
Stable value pooled separate account	-	12,394,322	-	12,394,322
Self-directed brokerage accounts	298,136	-	-	298,136
Total investments at fair value	<u>\$ 32,663,984</u>	<u>\$ 85,769,120</u>	<u>\$ -</u>	<u>\$ 118,433,104</u>

Note 5 – Stable Value Pooled Separate Account

The Plan's investment in the stable value pooled separate account (the "Fund"), a pooled separate account of PRIAC, is based on the fair value of the underlying investments. The investment objective is to receive a constant rate of return on the investments held in the Fund which is contractually agreed to (i.e., guaranteed) between the Plan and the Fund. The Plan's participants' accounts are credited with earnings on the underlying investments and charged for participant withdrawals and certain administrative expenses. PRIAC is contractually obligated to repay the principal and a specified interest rate in a manner that mimics contract value. Said rate is reset every six months, but fair value appreciation and gains and losses are rolled into the next six month fixed rate setting process. Generally, there are no restrictions on Plan participant's ability to redeem their investment in the Fund at a contract value rate. Certain affiliates of the Plan are also a part of this pooled separate account. Withdrawals prompted by certain events may restrict a participant's ability to redeem the investment. The contract does not permit PRIAC to terminate the agreement prior to the scheduled maturity date.

The Plan's ability to receive amounts due is dependent on PRIAC's ability to meet its financial obligations. PRIAC's ability to meet its contractual obligations may be affected by future economic and/or regulatory events.

Certain events limit the ability of the Plan to transact at the mimicked contract value with PRIAC. Such events include: (1) amendments to the Plan documents (including complete or partial Plan

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 5 – Stable Value Pooled Separate Account (continued)

termination or merger with another plan), (2) changes to the Plan's prohibition on competing investment options or deletion of equity wash provisions, (3) bankruptcy of the Plan sponsor or other Plan sponsor events (for example, divestitures or spin-offs of a subsidiary) that cause a significant withdrawal from the Plan, (4) the failure of the trust to qualify for exemption from federal income taxes or any required prohibited transaction exemption under ERISA, or (5) premature termination of the contract. The Plan administrator, as well as the Company and its management, believe that no events are probable of occurring that might limit the ability of the Plan to transact at contract value with the contract issuers and that also would limit the ability of the Plan to transact at contract value with the participants. The interest rates credited to participants in effect at December 31, 2021 and 2020 were 2.65% and 3.05%, respectively.

Note 6 – Plan Termination

Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants will become 100 percent vested in their employer contributions.

Note 7 – Tax Status

On February 8, 2013, the IRS stated that the Plan, as then designed, was in compliance with the applicable requirements of the Internal Revenue Code ("IRC"). Although the Plan has been amended since receiving the determination letter, the Plan administrator and the Plan's tax counsel believe that the Plan is designed and is currently being operated in compliance with the applicable requirements of the IRC and, therefore, believes that the Plan is qualified and the related trust is tax exempt.

The Prudential Non-Standardized Plan, effective January 1, 2022, received a favorable opinion letter dated December 4, 2020, in which the IRS stated that the Plan was in compliance with the applicable sections of the IRC.

U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020, no uncertain positions are taken or are expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

Note 8 – Related Party Transactions

The investments owned by the Plan are managed by PRIAC and PB&T, the trustees as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. Fees incurred by the Plan for the investment management services are included in net appreciation (depreciation) in fair value of investments, as they are paid by revenue sharing, rather than direct payment. The Plan made direct payments to the third party administrator of \$110,309 and \$93,665 for the years ended December 31, 2021 and 2020, respectively; which was not covered by revenue sharing. The Company pays directly any other fees related to the Plan's operations.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 9 – Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risks associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statement of net assets available for benefits.

The impact of the COVID-19 pandemic outbreak continues to evolve. Said pandemic has adversely affected net global economic activity. Because the values of the Plan's investments have and will fluctuate in response to these changing market conditions, the impact of this situation on the Plan (and the Company) and its future results and financial position is not presently determinable.

Note 10 – Benefits Payable

As of the date the financial statements were available to be issued, the Company had not completed the annual discrimination testing for the Plan for the year ended December 31, 2020. In addition, for an affiliated Plan in the controlled group (as defined), the discrimination testing has not been completed for the years ended December 31, 2021, 2020 and 2014. Management believes the amount of refunds, if any, resulting from the testing would not be material to the financial statements and, therefore, no liability has been recorded for such refunds, if any.

Note 11 – Subsequent Events

The Plan has evaluated subsequent events for potential recognition or disclosure in the financial statements through October 12, 2022, the date the financial statements were available to be issued.

As of April 1, 2022, Empower Retirement, LLC ("Empower") acquired the full service retirement business of Prudential Retirement. Additionally, Great-West Life & Annuity Insurance Company ("GWLA"), the parent company of Empower, acquired all shares of PRIAC and PB&T. As of this date, Empower became the administrator of all business acquired from Prudential.

In January 2022, FUJIFILM Diosynth Biotechnologies Holdings Delaware ("Diosynth Delaware"), an affiliate company, agreed with the Company and management to allow Diosynth Delaware to become a participating employer of the Plan effective January 1, 2022. As a result, employees of Diosynth Delaware are eligible to rollover their account balances into the Plan and become Plan participants.

In April 2022, FUJIFILM Diosynth Biotechnologies California Inc. ("Diosynth California"), an affiliate company, agreed with the Company and management to allow Diosynth California to become a participating employer of the Plan effective April 8, 2022. As a result, employees of Diosynth California are eligible to rollover their account balances into the Plan and become Plan participants.

Recent increases in inflation and interest rates, as well as other changes in economic and political events, have resulted in increased volatility in financial markets. Accordingly, the Plan's investment portfolio, subsequent to December 31, 2021, has incurred a decline in aggregate fair value. It is not known if values will continue to decline or how long a recovery, if any, of these values will take to recapture their peak values.

Supplementary Information

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Retirement Insurance and Annuity Company	FUJI Stable Value Pooled Separate Account		\$ 12,953,147
*	Prudential Retirement Insurance and Annuity Company	Small Cap Growth - Times Square		2,995,998
*	Prudential Retirement Insurance and Annuity Company	Small Cap Value - Integrity		2,995,999
*	Prudential Retirement Insurance and Annuity Company	Mid Cap Growth - Artisan Partners		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Allspring Special Mid Cap Value Fund		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Self-directed account		276,107
*	Prudential Retirement Insurance and Annuity Company	Large Cap Growth - T. Rowe Price Large Cap Growth Fund		8,529,426
*	Prudential Retirement Insurance and Annuity Company	T. Rowe Price Large Cap Value Equity Fund (IS)		8,529,426
*	Prudential Retirement Insurance and Annuity Company	Prudential Day One IncomeFlex Target Balanced Fund		2,880,330
*	Prudential Retirement Insurance and Annuity Company	Core Plus Bond / PGIM Fund		5,402,970
*	Prudential Retirement Insurance and Annuity Company	Dodge & Cox Intl Stock Fund		3,428,289
*	Prudential Retirement Insurance and Annuity Company	International Growth / Artisan Partners Fund		3,428,289
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Bond Market Index		3,274,363
*	Prudential Bank & Trust, F.S.B.	Fidelity Total Market Index Fund		13,433,953

See independent auditor's report.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2015		1,642,221
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2020		1,223,681
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2025		7,247,646
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2030		7,328,508
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2035		16,090,560
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2040		12,961,050
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2045		5,370,932
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2050		5,472,637
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2055		5,016,674
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2060		3,199,243
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2065		269,776
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement Income		1,134,461
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Intl Stock Index		7,312,116
				150,962,352
*	Notes receivable from participants	Interest rates ranging from 4.25% to 6.50%, various maturity dates, secured by participants' account balances	--	1,853,748
	Total			\$ 152,816,100

** Cost not required. (Investments are participant directed)

* Indicates an identified party known to be a party-in-interest to the Plan.

**FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONG TERM SAVINGS PLAN
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2021 AND 2020**

GETTRYMARCUS



**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan**

Table of Contents

Years Ended December 31, 2021 and 2020

	<u>Page</u>
Independent Auditor's Report	1-4
Financial Statements:	
Statements of Net Assets Available for Benefits.....	5
Statements of Changes in Net Assets Available for Benefits	6
Notes to Financial Statements	7-15
Supplementary Information:	
Schedule of Assets (Held at End of Year).....	16-17

Independent Auditor's Report

To the Board of Trustees
FUJIFILM Diosynth Biotechnologies Long Term Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements (the "2021 financial statements").

Management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section:

- The amounts and disclosures in the accompanying 2021 financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying 2021 financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section of our report. We are required to be independent of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the 2021 Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments, administering the plan, and determining that the plan's transactions that are presented and disclosed in the financial statements are in conformity with the plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit of the 2021 Financial Statements section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if, there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

2021 Supplemental Schedule Required by ERISA

The supplemental Schedule of Assets (Held at End of Year) as of December 31, 2021 is presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedule, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedule that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, other than the information agreed to or derived from the certified investment information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated October 13, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Gettry Marcus CPA, P.C.

Gettry Marcus CPA, P.C.
Woodbury, New York
October 12, 2022

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Net Assets Available for Benefits
December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets		
Investments - at fair value	<u>\$ 150,962,352</u>	<u>\$ 118,433,104</u>
Receivables		
Employer contribution	13,803	276,639
Notes receivable from participants	<u>1,853,748</u>	<u>1,539,855</u>
Total receivables	<u>1,867,551</u>	<u>1,816,494</u>
Net assets available for benefits	<u><u>\$ 152,829,903</u></u>	<u><u>\$ 120,249,598</u></u>

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Changes in Net Assets Available for Benefits
Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions:		
Additions to net assets attributed to:		
Investment income		
Net appreciation in fair value of investments	\$ 16,166,492	\$ 14,916,657
Interest	299,291	316,304
Dividends	430,597	337,332
Net investment income	<u>16,896,380</u>	<u>15,570,293</u>
Interest income on notes receivable from participants	<u>92,426</u>	<u>83,663</u>
Contributions		
Employer	11,029,745	8,535,372
Participants	10,673,099	8,238,361
Rollovers	3,690,277	1,356,335
Total contributions	<u>25,393,121</u>	<u>18,130,068</u>
Total additions	<u>42,381,927</u>	<u>33,784,024</u>
Deductions:		
Deductions from net assets attributed to:		
Benefits paid to participants	9,691,313	7,612,713
Administrative expenses	110,309	93,665
Total deductions	<u>9,801,622</u>	<u>7,706,378</u>
Net increase	32,580,305	26,077,646
Net assets available for benefits		
Beginning of year	<u>120,249,598</u>	<u>94,171,952</u>
End of year	<u>\$ 152,829,903</u>	<u>\$ 120,249,598</u>

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020**

Note 1 – Description of Plan

The following description of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the “Plan”) provides only general information. Participants should refer to the Plan agreement for a more complete description of the Plan’s provisions.

General

The Plan is a defined contribution plan established effective January 1, 2012. Non-union, non-leased employees of FUJIFILM Diosynth Biotechnologies U.S.A., Inc. and FUJIFILM Diosynth Biotechnologies Texas LLC (collectively the “Employer” or “Company”) become eligible to participate upon commencement of employment and attaining the age of 21. The Plan was established as a prototype 401(k) defined contribution plan of Prudential Retirement Insurance and Annuity Company (“PRIAC”). Effective January 1, 2022, the Plan adopted the Prudential Non-Standardized Pre-Approved Profit Sharing/401(k) Plan (“Prudential Non-Standardized Plan”). The Plan is subject to the provisions of ERISA. The Board of Trustees of the Plan is responsible for oversight of the Plan. Management of the Company determines the appropriateness of the Plan’s investment offerings, monitors investment performance and reports to the Plan’s Board of Trustees.

Contributions

Each year, participants may contribute a pre-tax amount equal to not less than 1% and not more than 65%, of their pretax compensation, as defined in the Plan. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. The Plan accepts Roth Elective Deferrals made on behalf of participants. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans (“rollover”). Effective April 1, 2014, an employee is automatically enrolled in the Plan at 6% of eligible compensation, increasing by 1% a year up to a total of 15%, unless opting not to have any contributions or a different amount made on their behalf. Participants may also make a post-tax contribution in an amount equal to not less than 1% and not more than 10% of their compensation. The contributions are automatically invested in an age appropriate qualified default investment alternative fund until changed by the participant. Participants direct the investment of their contributions, the employer contributions and rollovers into various investment options offered by the Plan. The Company will make a safe harbor matching contribution for eligible employees who have made 401(k) contributions. The amount shall be equal to 100% of the first 6% of the eligible employees’ compensation that they contribute to the Plan. The Company also makes a non-elective contribution on behalf of each eligible employee. For employees hired before December 31, 2014, the non-elective contribution amount is equal to a percentage of his compensation, based on their years of vesting service and determined in accordance with the table below. For employees hired after December 31, 2014, the non-elective contribution is 3% of their eligible compensation, regardless of vesting service. During the year ended December 31, 2021, the Company accrued a true up contribution for 2021 of \$520,081, of which \$506,278 was funded with forfeitures, which was paid in August 2022. The Company has not finalized its true up contribution for 2020. The Company intends to use additional forfeitures from periods subsequent to December 31, 2021 to fund the 2020 true up contribution when finalized, and does not believe there will be a material effect to the financial statements. During the year ended December 31, 2020, the Company accrued a true up contribution for 2019 of \$276,639 which was paid in February 2021. During the years ended December 31, 2021 and 2020, the Company made contributions of \$11,029,745 and \$8,535,372, which includes non-elective contributions of \$4,450,533 and \$3,390,653, respectively. Contributions are subject to certain Internal Revenue Service (“IRS”) limitations as noted below:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

<u>Years of Vesting Service</u>	<u>Percentage of Compensation</u>
0 – 9	3%
10 – 19	4%
20 – 29	5%
30+	6%

Participant Accounts

Each participant's account is credited with the participant's contributions and Company matching contributions as well as an allocation of (a) the Company's non-elective contribution, (b) Plan earnings and losses and (c) Plan administrative expenses. Earnings (losses) and investment expenses are allocated by fund based on the ratio of a participant's account invested in a particular fund to all participants' investments in that fund. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants immediately vest 100 percent in their voluntary employee and safe harbor matching contributions plus actual earnings thereon. The balance of vesting in the participants' accounts is based on years of continuous service. However, if an active participant dies or becomes totally and permanently disabled prior to attaining the normal retirement age, the participant's account balance becomes 100 percent vested.

Participants' vested interest in their non-elective contributions shall be determined in accordance with the following schedule:

<u>Years of Vesting Service</u>	<u>Vested Interest</u>
Less than 3 years	0%
3 years or more	100%

Forfeited Accounts

Forfeitures of non-vested benefits are used to reduce Company contributions and plan expenses. Forfeited non-vested accounts totaled \$573,733 and \$295,132 at December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and 2020, \$23,490 and \$36,786, respectively, were used to offset Plan expenses (\$23,490 in 2021 and \$33,807 in 2020) and Company contributions (\$-0- in 2021 and \$2,979 in 2020). In August 2022, the Company accrued a true up contribution for 2021, of which \$506,278 was funded with forfeitures.

Payment of Benefits

On termination of service, including death, disability or retirement, a participant will receive a lump-sum amount or an installment payment equal to the value of the participant's vested interest in his or her account. The participant becomes 100% vested in his or her non-elective contribution upon death, disability or normal retirement. If the vested interest in the participant's account is \$5,000 or less, the account will be distributed in a single-sum payment or by direct rollover to an IRA or other eligible retirement plan, even if the participant does not consent. If the value is greater than \$5,000, distribution of the account cannot be made before normal retirement age without written consent. Distributions are subject to the applicable provisions of the Plan agreement.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

Notes Receivable from Participants

Participants may borrow from their fund accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50 percent of their vested account balance. Loans may not be made from the portion of accounts attributable to nonelective contributions. The loans are secured by the balance in the participant's account and bear interest at rates of 4.25% to 6.50%, which is commensurate with the local prevailing rates as determined by the Plan administrator. The loans must be repaid over a period not to exceed five years or ten years for the purchase of a primary residence. Principal and interest are paid ratably through payroll deductions. Effective July 1, 2017, a participant who pays off an existing plan loan may not apply for another plan loan during the six-month period following the payoff date of the prior plan loan. For the period of May 12, 2020 through December 31, 2020, a participant who pays off an existing plan loan may not apply for another plan loan during the seven-day period following the payoff date of the prior plan loan.

Coronavirus Aid, Relief and Economic Security Act

The Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was enacted on March 27, 2020. The CARES Act includes a number of relief provisions available to tax-qualified retirement plans. The provisions of the CARES Act may be effective and operationalized immediately (i.e., prior to amending the Plan document). The Plan has adopted certain measures included in the CARES Act as follows:

- Permit qualified individuals (as defined under the CARES Act) to request Coronavirus-Related Distributions up to \$100,000 from their vested portion of the Plan between January 1, 2020 and December 31, 2020.
- For loans taken within 180 days after the enactment of the CARES Act (i.e., March 27, 2020), permit qualified CARES Act individuals to take loans from their account up to the lesser of 100% of their vested account balance or \$100,000. In addition, permit any Plan loan repayment that comes due during the period March 27, 2020 through December 31, 2020 to be delayed for up to one year.
- Permit the delay of Required Minimum Distributions ("RMD") for a period of one year, with the delay applying to both 2019 distributions that were required to begin no later than April 1, 2020, and 2020 distributions, unless an employee elects to receive an RMD in 2020. Participants electing to receive a 2020 RMD amount are able to use the 60-day rollover option.

The timing and manner for formal plan amendments, as determined by the CARES Act, is for the Plan year ending December 31, 2022; however, the timing of the RMD provision was extended to the Plan year ending December 31, 2025.

Note 2 – Summary of Accounting Policies

Basis of Accounting

The financial statements of the Plan are prepared on the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and changes therein and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020**

Note 2 – Summary of Accounting Policies (continued)

Investment Valuation and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management of the Company determines the Plan's valuation policies utilizing information provided by the Plan's investment advisers, custodians and insurance company.

Purchases and sales of securities are recorded on a trade date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Interest income is recorded on an accrual basis. Related fees are recorded as administrative expenses and are expensed as incurred. No allowance for credit losses have been recorded as of December 31, 2021 and 2020. If a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded. Defaulted loans recorded as benefit payments amounted to \$97,987 and \$73,873 for the years ended December 31, 2021 and 2020, respectively.

Payments of Benefits

Benefits are recorded when paid by the Plan.

Administrative Expenses

The Plan's expenses are paid either by the Plan or the Company as provided by the Plan agreement. Certain administrative expenses of the Plan that are paid by the Plan are recorded as deductions in the accompanying statements of changes in net assets available for benefits. Expenses that are paid by the Company are excluded from these financial statements. Fees related to the administration of notes receivable from participants are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation of fair value of investments.

Accounting Standards Update ("ASU")

On August 28, 2018, FASB issued ASU 2018-13, Disclosure Framework—Changes to the Disclosure Requirement for Fair Value Measurement (Topic 820). The ASU, which applies to all entities (including defined contribution plans) removes, modifies and adds fair value and/or NAV related disclosures. The ASU is effective for years beginning after December 15, 2019. The Board of Trustees has determined that the adoption of ASU 2018-13 has no impact on its financial statements.

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.

The following information included in the accompanying financial statements and supplemental schedules was obtained from data that has been prepared and certified to as complete and accurate by PRIAC and Prudential Bank & Trust, F.S.B. ("PB&T"), (the trustees of the Plan), except for the stable value pooled separate account, which is only certified at its contract value at December 31, 2021 and 2020 of \$12,583,755 and \$11,763,491, respectively, for which the fair value adjustments of \$369,392 and \$630,831, respectively, and changes in adjustments from contract value to fair value of \$(261,439) and \$299,354, respectively, are not certified:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.
(continued)

	<u>2021</u>	<u>2020</u>
Investments:		
Pooled separate accounts	\$ 30,515,287	\$ 24,161,658
Mutual funds	40,260,422	32,365,848
Common/collective trusts	66,957,389	49,213,140
Stable value pooled separate account	12,583,755	11,763,491
Self-directed brokerage accounts	276,107	298,136
Total Investments	<u>\$ 150,592,960</u>	<u>\$ 117,802,273</u>
Notes receivable from participants	<u>\$ 1,853,748</u>	<u>\$ 1,539,855</u>
Interest income on notes receivable from participants	<u>\$ 92,426</u>	<u>\$ 83,663</u>
Investment income:		
Net appreciation in fair value of investments	\$ 16,427,931	\$ 14,617,303
Dividends	299,291	316,304
Interest	430,597	337,332
Total investment income	<u>\$ 17,157,819</u>	<u>\$ 15,270,939</u>

The assets of the Plan are invested at the direction of the participants in various investment funds at December 31, 2021 and 2020.

Note 4 – Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
---------	---

Level 2 Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
---------	---

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2021 and 2020.

Pooled separate accounts: Valued at fair value based on the current market values of the underlying assets of the fund.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Stable value pooled separate account: The stable value pooled separate account is not available in an exchange and active market, however, the fair value is determined based on the Plan's pro-rata share of the underlying investments in the pooled separate account. The underlying investments are principally comprised of investment grade: mortgage pools, corporate bonds and U.S. and foreign government bonds. Values are determined by quoted prices, market indexes, and bid and asked criteria.

Common/collective trusts: Valued at the daily closing price as reported by the fund. Common/collective trusts held by the Plan are composed of target retirement funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The target retirement funds held by the Plan are deemed to be actively traded.

Self-directed brokerage accounts: Consists of interest bearing cash, common stocks and mutual funds. The common stocks are valued at the closing price reported in the active market in which the individual securities are traded. The mutual funds are valued at the NAV of shares held by the Plan at year end. Cash is valued at fair value based on current market values of the underlying assets of the fund.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's investments at fair value at December 31, 2021 and 2020:

Investments at Fair Value at December 31, 2021

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 30,515,287	\$ -	\$ 30,515,287
Mutual funds	40,260,422	-	-	40,260,422
Common/collective trusts	-	66,957,389	-	66,957,389
Stable value pooled separate account	-	12,953,147	-	12,953,147
Self-directed brokerage accounts	276,107	-	-	276,107
Total investments at fair value	<u>\$ 40,536,529</u>	<u>\$ 110,425,823</u>	<u>\$ -</u>	<u>\$ 150,962,352</u>

Investments at Fair Value at December 31, 2020

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 24,161,658	\$ -	\$ 24,161,658
Mutual funds	32,365,848	-	-	32,365,848
Common/collective trusts	-	49,213,140	-	49,213,140
Stable value pooled separate account	-	12,394,322	-	12,394,322
Self-directed brokerage accounts	298,136	-	-	298,136
Total investments at fair value	<u>\$ 32,663,984</u>	<u>\$ 85,769,120</u>	<u>\$ -</u>	<u>\$ 118,433,104</u>

Note 5 – Stable Value Pooled Separate Account

The Plan's investment in the stable value pooled separate account (the "Fund"), a pooled separate account of PRIAC, is based on the fair value of the underlying investments. The investment objective is to receive a constant rate of return on the investments held in the Fund which is contractually agreed to (i.e., guaranteed) between the Plan and the Fund. The Plan's participants' accounts are credited with earnings on the underlying investments and charged for participant withdrawals and certain administrative expenses. PRIAC is contractually obligated to repay the principal and a specified interest rate in a manner that mimics contract value. Said rate is reset every six months, but fair value appreciation and gains and losses are rolled into the next six month fixed rate setting process. Generally, there are no restrictions on Plan participant's ability to redeem their investment in the Fund at a contract value rate. Certain affiliates of the Plan are also a part of this pooled separate account. Withdrawals prompted by certain events may restrict a participant's ability to redeem the investment. The contract does not permit PRIAC to terminate the agreement prior to the scheduled maturity date.

The Plan's ability to receive amounts due is dependent on PRIAC's ability to meet its financial obligations. PRIAC's ability to meet its contractual obligations may be affected by future economic and/or regulatory events.

Certain events limit the ability of the Plan to transact at the mimicked contract value with PRIAC. Such events include: (1) amendments to the Plan documents (including complete or partial Plan

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 5 – Stable Value Pooled Separate Account (continued)

termination or merger with another plan), (2) changes to the Plan's prohibition on competing investment options or deletion of equity wash provisions, (3) bankruptcy of the Plan sponsor or other Plan sponsor events (for example, divestitures or spin-offs of a subsidiary) that cause a significant withdrawal from the Plan, (4) the failure of the trust to qualify for exemption from federal income taxes or any required prohibited transaction exemption under ERISA, or (5) premature termination of the contract. The Plan administrator, as well as the Company and its management, believe that no events are probable of occurring that might limit the ability of the Plan to transact at contract value with the contract issuers and that also would limit the ability of the Plan to transact at contract value with the participants. The interest rates credited to participants in effect at December 31, 2021 and 2020 were 2.65% and 3.05%, respectively.

Note 6 – Plan Termination

Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants will become 100 percent vested in their employer contributions.

Note 7 – Tax Status

On February 8, 2013, the IRS stated that the Plan, as then designed, was in compliance with the applicable requirements of the Internal Revenue Code ("IRC"). Although the Plan has been amended since receiving the determination letter, the Plan administrator and the Plan's tax counsel believe that the Plan is designed and is currently being operated in compliance with the applicable requirements of the IRC and, therefore, believes that the Plan is qualified and the related trust is tax exempt.

The Prudential Non-Standardized Plan, effective January 1, 2022, received a favorable opinion letter dated December 4, 2020, in which the IRS stated that the Plan was in compliance with the applicable sections of the IRC.

U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020, no uncertain positions are taken or are expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

Note 8 – Related Party Transactions

The investments owned by the Plan are managed by PRIAC and PB&T, the trustees as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. Fees incurred by the Plan for the investment management services are included in net appreciation (depreciation) in fair value of investments, as they are paid by revenue sharing, rather than direct payment. The Plan made direct payments to the third party administrator of \$110,309 and \$93,665 for the years ended December 31, 2021 and 2020, respectively; which was not covered by revenue sharing. The Company pays directly any other fees related to the Plan's operations.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 9 – Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risks associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statement of net assets available for benefits.

The impact of the COVID-19 pandemic outbreak continues to evolve. Said pandemic has adversely affected net global economic activity. Because the values of the Plan's investments have and will fluctuate in response to these changing market conditions, the impact of this situation on the Plan (and the Company) and its future results and financial position is not presently determinable.

Note 10 – Benefits Payable

As of the date the financial statements were available to be issued, the Company had not completed the annual discrimination testing for the Plan for the year ended December 31, 2020. In addition, for an affiliated Plan in the controlled group (as defined), the discrimination testing has not been completed for the years ended December 31, 2021, 2020 and 2014. Management believes the amount of refunds, if any, resulting from the testing would not be material to the financial statements and, therefore, no liability has been recorded for such refunds, if any.

Note 11 – Subsequent Events

The Plan has evaluated subsequent events for potential recognition or disclosure in the financial statements through October 12, 2022, the date the financial statements were available to be issued.

As of April 1, 2022, Empower Retirement, LLC ("Empower") acquired the full service retirement business of Prudential Retirement. Additionally, Great-West Life & Annuity Insurance Company ("GWLA"), the parent company of Empower, acquired all shares of PRIAC and PB&T. As of this date, Empower became the administrator of all business acquired from Prudential.

In January 2022, FUJIFILM Diosynth Biotechnologies Holdings Delaware ("Diosynth Delaware"), an affiliate company, agreed with the Company and management to allow Diosynth Delaware to become a participating employer of the Plan effective January 1, 2022. As a result, employees of Diosynth Delaware are eligible to rollover their account balances into the Plan and become Plan participants.

In April 2022, FUJIFILM Diosynth Biotechnologies California Inc. ("Diosynth California"), an affiliate company, agreed with the Company and management to allow Diosynth California to become a participating employer of the Plan effective April 8, 2022. As a result, employees of Diosynth California are eligible to rollover their account balances into the Plan and become Plan participants.

Recent increases in inflation and interest rates, as well as other changes in economic and political events, have resulted in increased volatility in financial markets. Accordingly, the Plan's investment portfolio, subsequent to December 31, 2021, has incurred a decline in aggregate fair value. It is not known if values will continue to decline or how long a recovery, if any, of these values will take to recapture their peak values.

Supplementary Information

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Retirement Insurance and Annuity Company	FUJI Stable Value Pooled Separate Account		\$ 12,953,147
*	Prudential Retirement Insurance and Annuity Company	Small Cap Growth - Times Square		2,995,998
*	Prudential Retirement Insurance and Annuity Company	Small Cap Value - Integrity		2,995,999
*	Prudential Retirement Insurance and Annuity Company	Mid Cap Growth - Artisan Partners		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Allspring Special Mid Cap Value Fund		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Self-directed account		276,107
*	Prudential Retirement Insurance and Annuity Company	Large Cap Growth - T. Rowe Price Large Cap Growth Fund		8,529,426
*	Prudential Retirement Insurance and Annuity Company	T. Rowe Price Large Cap Value Equity Fund (IS)		8,529,426
*	Prudential Retirement Insurance and Annuity Company	Prudential Day One IncomeFlex Target Balanced Fund		2,880,330
*	Prudential Retirement Insurance and Annuity Company	Core Plus Bond / PGIM Fund		5,402,970
*	Prudential Retirement Insurance and Annuity Company	Dodge & Cox Intl Stock Fund		3,428,289
*	Prudential Retirement Insurance and Annuity Company	International Growth / Artisan Partners Fund		3,428,289
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Bond Market Index		3,274,363
*	Prudential Bank & Trust, F.S.B.	Fidelity Total Market Index Fund		13,433,953

See independent auditor's report.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2015		1,642,221
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2020		1,223,681
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2025		7,247,646
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2030		7,328,508
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2035		16,090,560
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2040		12,961,050
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2045		5,370,932
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2050		5,472,637
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2055		5,016,674
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2060		3,199,243
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2065		269,776
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement Income		1,134,461
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Intl Stock Index		7,312,116
				150,962,352
*	Notes receivable from participants	Interest rates ranging from 4.25% to 6.50%, various maturity dates, secured by participants' account balances	--	1,853,748
	Total			\$ 152,816,100

** Cost not required. (Investments are participant directed)

* Indicates an identified party known to be a party-in-interest to the Plan.

**FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONG TERM SAVINGS PLAN
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2021 AND 2020**

GETTRYMARCUS



**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan**

Table of Contents

Years Ended December 31, 2021 and 2020

	<u>Page</u>
Independent Auditor's Report	1-4
Financial Statements:	
Statements of Net Assets Available for Benefits.....	5
Statements of Changes in Net Assets Available for Benefits	6
Notes to Financial Statements	7-15
Supplementary Information:	
Schedule of Assets (Held at End of Year).....	16-17

Independent Auditor's Report

To the Board of Trustees
FUJIFILM Diosynth Biotechnologies Long Term Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements (the "2021 financial statements").

Management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section:

- The amounts and disclosures in the accompanying 2021 financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying 2021 financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the 2021 Financial Statements section of our report. We are required to be independent of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the 2021 Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments, administering the plan, and determining that the plan's transactions that are presented and disclosed in the financial statements are in conformity with the plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit of the 2021 Financial Statements section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if, there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about FUJIFILM Diosynth Biotechnologies Long Term Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

2021 Supplemental Schedule Required by ERISA

The supplemental Schedule of Assets (Held at End of Year) as of December 31, 2021 is presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedule, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedule that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, other than the information agreed to or derived from the certified investment information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated October 13, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Gettry Marcus CPA, P.C.

Gettry Marcus CPA, P.C.
Woodbury, New York
October 12, 2022

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Net Assets Available for Benefits
December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets		
Investments - at fair value	<u>\$ 150,962,352</u>	<u>\$ 118,433,104</u>
Receivables		
Employer contribution	13,803	276,639
Notes receivable from participants	<u>1,853,748</u>	<u>1,539,855</u>
Total receivables	<u>1,867,551</u>	<u>1,816,494</u>
Net assets available for benefits	<u><u>\$ 152,829,903</u></u>	<u><u>\$ 120,249,598</u></u>

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Statements of Changes in Net Assets Available for Benefits
Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions:		
Additions to net assets attributed to:		
Investment income		
Net appreciation in fair value of investments	\$ 16,166,492	\$ 14,916,657
Interest	299,291	316,304
Dividends	430,597	337,332
Net investment income	<u>16,896,380</u>	<u>15,570,293</u>
Interest income on notes receivable from participants	<u>92,426</u>	<u>83,663</u>
Contributions		
Employer	11,029,745	8,535,372
Participants	10,673,099	8,238,361
Rollovers	3,690,277	1,356,335
Total contributions	<u>25,393,121</u>	<u>18,130,068</u>
Total additions	<u>42,381,927</u>	<u>33,784,024</u>
Deductions:		
Deductions from net assets attributed to:		
Benefits paid to participants	9,691,313	7,612,713
Administrative expenses	110,309	93,665
Total deductions	<u>9,801,622</u>	<u>7,706,378</u>
Net increase	32,580,305	26,077,646
Net assets available for benefits		
Beginning of year	<u>120,249,598</u>	<u>94,171,952</u>
End of year	<u>\$ 152,829,903</u>	<u>\$ 120,249,598</u>

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020**

Note 1 – Description of Plan

The following description of FUJIFILM Diosynth Biotechnologies Long Term Savings Plan (the “Plan”) provides only general information. Participants should refer to the Plan agreement for a more complete description of the Plan’s provisions.

General

The Plan is a defined contribution plan established effective January 1, 2012. Non-union, non-leased employees of FUJIFILM Diosynth Biotechnologies U.S.A., Inc. and FUJIFILM Diosynth Biotechnologies Texas LLC (collectively the “Employer” or “Company”) become eligible to participate upon commencement of employment and attaining the age of 21. The Plan was established as a prototype 401(k) defined contribution plan of Prudential Retirement Insurance and Annuity Company (“PRIAC”). Effective January 1, 2022, the Plan adopted the Prudential Non-Standardized Pre-Approved Profit Sharing/401(k) Plan (“Prudential Non-Standardized Plan”). The Plan is subject to the provisions of ERISA. The Board of Trustees of the Plan is responsible for oversight of the Plan. Management of the Company determines the appropriateness of the Plan’s investment offerings, monitors investment performance and reports to the Plan’s Board of Trustees.

Contributions

Each year, participants may contribute a pre-tax amount equal to not less than 1% and not more than 65%, of their pretax compensation, as defined in the Plan. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. The Plan accepts Roth Elective Deferrals made on behalf of participants. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans (“rollover”). Effective April 1, 2014, an employee is automatically enrolled in the Plan at 6% of eligible compensation, increasing by 1% a year up to a total of 15%, unless opting not to have any contributions or a different amount made on their behalf. Participants may also make a post-tax contribution in an amount equal to not less than 1% and not more than 10% of their compensation. The contributions are automatically invested in an age appropriate qualified default investment alternative fund until changed by the participant. Participants direct the investment of their contributions, the employer contributions and rollovers into various investment options offered by the Plan. The Company will make a safe harbor matching contribution for eligible employees who have made 401(k) contributions. The amount shall be equal to 100% of the first 6% of the eligible employees’ compensation that they contribute to the Plan. The Company also makes a non-elective contribution on behalf of each eligible employee. For employees hired before December 31, 2014, the non-elective contribution amount is equal to a percentage of his compensation, based on their years of vesting service and determined in accordance with the table below. For employees hired after December 31, 2014, the non-elective contribution is 3% of their eligible compensation, regardless of vesting service. During the year ended December 31, 2021, the Company accrued a true up contribution for 2021 of \$520,081, of which \$506,278 was funded with forfeitures, which was paid in August 2022. The Company has not finalized its true up contribution for 2020. The Company intends to use additional forfeitures from periods subsequent to December 31, 2021 to fund the 2020 true up contribution when finalized, and does not believe there will be a material effect to the financial statements. During the year ended December 31, 2020, the Company accrued a true up contribution for 2019 of \$276,639 which was paid in February 2021. During the years ended December 31, 2021 and 2020, the Company made contributions of \$11,029,745 and \$8,535,372, which includes non-elective contributions of \$4,450,533 and \$3,390,653, respectively. Contributions are subject to certain Internal Revenue Service (“IRS”) limitations as noted below:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

<u>Years of Vesting Service</u>	<u>Percentage of Compensation</u>
0 – 9	3%
10 – 19	4%
20 – 29	5%
30+	6%

Participant Accounts

Each participant's account is credited with the participant's contributions and Company matching contributions as well as an allocation of (a) the Company's non-elective contribution, (b) Plan earnings and losses and (c) Plan administrative expenses. Earnings (losses) and investment expenses are allocated by fund based on the ratio of a participant's account invested in a particular fund to all participants' investments in that fund. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants immediately vest 100 percent in their voluntary employee and safe harbor matching contributions plus actual earnings thereon. The balance of vesting in the participants' accounts is based on years of continuous service. However, if an active participant dies or becomes totally and permanently disabled prior to attaining the normal retirement age, the participant's account balance becomes 100 percent vested.

Participants' vested interest in their non-elective contributions shall be determined in accordance with the following schedule:

<u>Years of Vesting Service</u>	<u>Vested Interest</u>
Less than 3 years	0%
3 years or more	100%

Forfeited Accounts

Forfeitures of non-vested benefits are used to reduce Company contributions and plan expenses. Forfeited non-vested accounts totaled \$573,733 and \$295,132 at December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and 2020, \$23,490 and \$36,786, respectively, were used to offset Plan expenses (\$23,490 in 2021 and \$33,807 in 2020) and Company contributions (\$-0- in 2021 and \$2,979 in 2020). In August 2022, the Company accrued a true up contribution for 2021, of which \$506,278 was funded with forfeitures.

Payment of Benefits

On termination of service, including death, disability or retirement, a participant will receive a lump-sum amount or an installment payment equal to the value of the participant's vested interest in his or her account. The participant becomes 100% vested in his or her non-elective contribution upon death, disability or normal retirement. If the vested interest in the participant's account is \$5,000 or less, the account will be distributed in a single-sum payment or by direct rollover to an IRA or other eligible retirement plan, even if the participant does not consent. If the value is greater than \$5,000, distribution of the account cannot be made before normal retirement age without written consent. Distributions are subject to the applicable provisions of the Plan agreement.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 1 – Description of Plan (continued)

Notes Receivable from Participants

Participants may borrow from their fund accounts a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50 percent of their vested account balance. Loans may not be made from the portion of accounts attributable to nonelective contributions. The loans are secured by the balance in the participant's account and bear interest at rates of 4.25% to 6.50%, which is commensurate with the local prevailing rates as determined by the Plan administrator. The loans must be repaid over a period not to exceed five years or ten years for the purchase of a primary residence. Principal and interest are paid ratably through payroll deductions. Effective July 1, 2017, a participant who pays off an existing plan loan may not apply for another plan loan during the six-month period following the payoff date of the prior plan loan. For the period of May 12, 2020 through December 31, 2020, a participant who pays off an existing plan loan may not apply for another plan loan during the seven-day period following the payoff date of the prior plan loan.

Coronavirus Aid, Relief and Economic Security Act

The Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was enacted on March 27, 2020. The CARES Act includes a number of relief provisions available to tax-qualified retirement plans. The provisions of the CARES Act may be effective and operationalized immediately (i.e., prior to amending the Plan document). The Plan has adopted certain measures included in the CARES Act as follows:

- Permit qualified individuals (as defined under the CARES Act) to request Coronavirus-Related Distributions up to \$100,000 from their vested portion of the Plan between January 1, 2020 and December 31, 2020.
- For loans taken within 180 days after the enactment of the CARES Act (i.e., March 27, 2020), permit qualified CARES Act individuals to take loans from their account up to the lesser of 100% of their vested account balance or \$100,000. In addition, permit any Plan loan repayment that comes due during the period March 27, 2020 through December 31, 2020 to be delayed for up to one year.
- Permit the delay of Required Minimum Distributions ("RMD") for a period of one year, with the delay applying to both 2019 distributions that were required to begin no later than April 1, 2020, and 2020 distributions, unless an employee elects to receive an RMD in 2020. Participants electing to receive a 2020 RMD amount are able to use the 60-day rollover option.

The timing and manner for formal plan amendments, as determined by the CARES Act, is for the Plan year ending December 31, 2022; however, the timing of the RMD provision was extended to the Plan year ending December 31, 2025.

Note 2 – Summary of Accounting Policies

Basis of Accounting

The financial statements of the Plan are prepared on the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and changes therein and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 2 – Summary of Accounting Policies (continued)

Investment Valuation and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management of the Company determines the Plan's valuation policies utilizing information provided by the Plan's investment advisers, custodians and insurance company.

Purchases and sales of securities are recorded on a trade date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Interest income is recorded on an accrual basis. Related fees are recorded as administrative expenses and are expensed as incurred. No allowance for credit losses have been recorded as of December 31, 2021 and 2020. If a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded. Defaulted loans recorded as benefit payments amounted to \$97,987 and \$73,873 for the years ended December 31, 2021 and 2020, respectively.

Payments of Benefits

Benefits are recorded when paid by the Plan.

Administrative Expenses

The Plan's expenses are paid either by the Plan or the Company as provided by the Plan agreement. Certain administrative expenses of the Plan that are paid by the Plan are recorded as deductions in the accompanying statements of changes in net assets available for benefits. Expenses that are paid by the Company are excluded from these financial statements. Fees related to the administration of notes receivable from participants are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation of fair value of investments.

Accounting Standards Update ("ASU")

On August 28, 2018, FASB issued ASU 2018-13, Disclosure Framework—Changes to the Disclosure Requirement for Fair Value Measurement (Topic 820). The ASU, which applies to all entities (including defined contribution plans) removes, modifies and adds fair value and/or NAV related disclosures. The ASU is effective for years beginning after December 15, 2019. The Board of Trustees has determined that the adoption of ASU 2018-13 has no impact on its financial statements.

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.

The following information included in the accompanying financial statements and supplemental schedules was obtained from data that has been prepared and certified to as complete and accurate by PRIAC and Prudential Bank & Trust, F.S.B. ("PB&T"), (the trustees of the Plan), except for the stable value pooled separate account, which is only certified at its contract value at December 31, 2021 and 2020 of \$12,583,755 and \$11,763,491, respectively, for which the fair value adjustments of \$369,392 and \$630,831, respectively, and changes in adjustments from contract value to fair value of \$(261,439) and \$299,354, respectively, are not certified:

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 3 – Information Prepared and Certified by PRIAC and Prudential Bank and Trust, F.S.B.
(continued)

	<u>2021</u>	<u>2020</u>
Investments:		
Pooled separate accounts	\$ 30,515,287	\$ 24,161,658
Mutual funds	40,260,422	32,365,848
Common/collective trusts	66,957,389	49,213,140
Stable value pooled separate account	12,583,755	11,763,491
Self-directed brokerage accounts	276,107	298,136
Total Investments	<u>\$ 150,592,960</u>	<u>\$ 117,802,273</u>
Notes receivable from participants	<u>\$ 1,853,748</u>	<u>\$ 1,539,855</u>
Interest income on notes receivable from participants	<u>\$ 92,426</u>	<u>\$ 83,663</u>
Investment income:		
Net appreciation in fair value of investments	\$ 16,427,931	\$ 14,617,303
Dividends	299,291	316,304
Interest	430,597	337,332
Total investment income	<u>\$ 17,157,819</u>	<u>\$ 15,270,939</u>

The assets of the Plan are invested at the direction of the participants in various investment funds at December 31, 2021 and 2020.

Note 4 – Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
---------	---

Level 2 Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3	Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
---------	---

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2021 and 2020.

Pooled separate accounts: Valued at fair value based on the current market values of the underlying assets of the fund.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Stable value pooled separate account: The stable value pooled separate account is not available in an exchange and active market, however, the fair value is determined based on the Plan's pro-rata share of the underlying investments in the pooled separate account. The underlying investments are principally comprised of investment grade: mortgage pools, corporate bonds and U.S. and foreign government bonds. Values are determined by quoted prices, market indexes, and bid and asked criteria.

Common/collective trusts: Valued at the daily closing price as reported by the fund. Common/collective trusts held by the Plan are composed of target retirement funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The target retirement funds held by the Plan are deemed to be actively traded.

Self-directed brokerage accounts: Consists of interest bearing cash, common stocks and mutual funds. The common stocks are valued at the closing price reported in the active market in which the individual securities are traded. The mutual funds are valued at the NAV of shares held by the Plan at year end. Cash is valued at fair value based on current market values of the underlying assets of the fund.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 4 – Fair Value Measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Plan's investments at fair value at December 31, 2021 and 2020:

Investments at Fair Value at December 31, 2021

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 30,515,287	\$ -	\$ 30,515,287
Mutual funds	40,260,422	-	-	40,260,422
Common/collective trusts	-	66,957,389	-	66,957,389
Stable value pooled separate account	-	12,953,147	-	12,953,147
Self-directed brokerage accounts	276,107	-	-	276,107
Total investments at fair value	<u>\$ 40,536,529</u>	<u>\$ 110,425,823</u>	<u>\$ -</u>	<u>\$ 150,962,352</u>

Investments at Fair Value at December 31, 2020

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Pooled separate accounts:				
Equity securities	\$ -	\$ 24,161,658	\$ -	\$ 24,161,658
Mutual funds	32,365,848	-	-	32,365,848
Common/collective trusts	-	49,213,140	-	49,213,140
Stable value pooled separate account	-	12,394,322	-	12,394,322
Self-directed brokerage accounts	298,136	-	-	298,136
Total investments at fair value	<u>\$ 32,663,984</u>	<u>\$ 85,769,120</u>	<u>\$ -</u>	<u>\$ 118,433,104</u>

Note 5 – Stable Value Pooled Separate Account

The Plan's investment in the stable value pooled separate account (the "Fund"), a pooled separate account of PRIAC, is based on the fair value of the underlying investments. The investment objective is to receive a constant rate of return on the investments held in the Fund which is contractually agreed to (i.e., guaranteed) between the Plan and the Fund. The Plan's participants' accounts are credited with earnings on the underlying investments and charged for participant withdrawals and certain administrative expenses. PRIAC is contractually obligated to repay the principal and a specified interest rate in a manner that mimics contract value. Said rate is reset every six months, but fair value appreciation and gains and losses are rolled into the next six month fixed rate setting process. Generally, there are no restrictions on Plan participant's ability to redeem their investment in the Fund at a contract value rate. Certain affiliates of the Plan are also a part of this pooled separate account. Withdrawals prompted by certain events may restrict a participant's ability to redeem the investment. The contract does not permit PRIAC to terminate the agreement prior to the scheduled maturity date.

The Plan's ability to receive amounts due is dependent on PRIAC's ability to meet its financial obligations. PRIAC's ability to meet its contractual obligations may be affected by future economic and/or regulatory events.

Certain events limit the ability of the Plan to transact at the mimicked contract value with PRIAC. Such events include: (1) amendments to the Plan documents (including complete or partial Plan

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 5 – Stable Value Pooled Separate Account (continued)

termination or merger with another plan), (2) changes to the Plan's prohibition on competing investment options or deletion of equity wash provisions, (3) bankruptcy of the Plan sponsor or other Plan sponsor events (for example, divestitures or spin-offs of a subsidiary) that cause a significant withdrawal from the Plan, (4) the failure of the trust to qualify for exemption from federal income taxes or any required prohibited transaction exemption under ERISA, or (5) premature termination of the contract. The Plan administrator, as well as the Company and its management, believe that no events are probable of occurring that might limit the ability of the Plan to transact at contract value with the contract issuers and that also would limit the ability of the Plan to transact at contract value with the participants. The interest rates credited to participants in effect at December 31, 2021 and 2020 were 2.65% and 3.05%, respectively.

Note 6 – Plan Termination

Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants will become 100 percent vested in their employer contributions.

Note 7 – Tax Status

On February 8, 2013, the IRS stated that the Plan, as then designed, was in compliance with the applicable requirements of the Internal Revenue Code ("IRC"). Although the Plan has been amended since receiving the determination letter, the Plan administrator and the Plan's tax counsel believe that the Plan is designed and is currently being operated in compliance with the applicable requirements of the IRC and, therefore, believes that the Plan is qualified and the related trust is tax exempt.

The Prudential Non-Standardized Plan, effective January 1, 2022, received a favorable opinion letter dated December 4, 2020, in which the IRS stated that the Plan was in compliance with the applicable sections of the IRC.

U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020, no uncertain positions are taken or are expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

Note 8 – Related Party Transactions

The investments owned by the Plan are managed by PRIAC and PB&T, the trustees as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. Fees incurred by the Plan for the investment management services are included in net appreciation (depreciation) in fair value of investments, as they are paid by revenue sharing, rather than direct payment. The Plan made direct payments to the third party administrator of \$110,309 and \$93,665 for the years ended December 31, 2021 and 2020, respectively; which was not covered by revenue sharing. The Company pays directly any other fees related to the Plan's operations.

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Notes to Financial Statements
December 31, 2021 and 2020

Note 9 – Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risks associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statement of net assets available for benefits.

The impact of the COVID-19 pandemic outbreak continues to evolve. Said pandemic has adversely affected net global economic activity. Because the values of the Plan's investments have and will fluctuate in response to these changing market conditions, the impact of this situation on the Plan (and the Company) and its future results and financial position is not presently determinable.

Note 10 – Benefits Payable

As of the date the financial statements were available to be issued, the Company had not completed the annual discrimination testing for the Plan for the year ended December 31, 2020. In addition, for an affiliated Plan in the controlled group (as defined), the discrimination testing has not been completed for the years ended December 31, 2021, 2020 and 2014. Management believes the amount of refunds, if any, resulting from the testing would not be material to the financial statements and, therefore, no liability has been recorded for such refunds, if any.

Note 11 – Subsequent Events

The Plan has evaluated subsequent events for potential recognition or disclosure in the financial statements through October 12, 2022, the date the financial statements were available to be issued.

As of April 1, 2022, Empower Retirement, LLC ("Empower") acquired the full service retirement business of Prudential Retirement. Additionally, Great-West Life & Annuity Insurance Company ("GWLA"), the parent company of Empower, acquired all shares of PRIAC and PB&T. As of this date, Empower became the administrator of all business acquired from Prudential.

In January 2022, FUJIFILM Diosynth Biotechnologies Holdings Delaware ("Diosynth Delaware"), an affiliate company, agreed with the Company and management to allow Diosynth Delaware to become a participating employer of the Plan effective January 1, 2022. As a result, employees of Diosynth Delaware are eligible to rollover their account balances into the Plan and become Plan participants.

In April 2022, FUJIFILM Diosynth Biotechnologies California Inc. ("Diosynth California"), an affiliate company, agreed with the Company and management to allow Diosynth California to become a participating employer of the Plan effective April 8, 2022. As a result, employees of Diosynth California are eligible to rollover their account balances into the Plan and become Plan participants.

Recent increases in inflation and interest rates, as well as other changes in economic and political events, have resulted in increased volatility in financial markets. Accordingly, the Plan's investment portfolio, subsequent to December 31, 2021, has incurred a decline in aggregate fair value. It is not known if values will continue to decline or how long a recovery, if any, of these values will take to recapture their peak values.

Supplementary Information

FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Retirement Insurance and Annuity Company	FUJI Stable Value Pooled Separate Account		\$ 12,953,147
*	Prudential Retirement Insurance and Annuity Company	Small Cap Growth - Times Square		2,995,998
*	Prudential Retirement Insurance and Annuity Company	Small Cap Value - Integrity		2,995,999
*	Prudential Retirement Insurance and Annuity Company	Mid Cap Growth - Artisan Partners		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Allspring Special Mid Cap Value Fund		4,282,275
*	Prudential Retirement Insurance and Annuity Company	Self-directed account		276,107
*	Prudential Retirement Insurance and Annuity Company	Large Cap Growth - T. Rowe Price Large Cap Growth Fund		8,529,426
*	Prudential Retirement Insurance and Annuity Company	T. Rowe Price Large Cap Value Equity Fund (IS)		8,529,426
*	Prudential Retirement Insurance and Annuity Company	Prudential Day One IncomeFlex Target Balanced Fund		2,880,330
*	Prudential Retirement Insurance and Annuity Company	Core Plus Bond / PGIM Fund		5,402,970
*	Prudential Retirement Insurance and Annuity Company	Dodge & Cox Intl Stock Fund		3,428,289
*	Prudential Retirement Insurance and Annuity Company	International Growth / Artisan Partners Fund		3,428,289
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Bond Market Index		3,274,363
*	Prudential Bank & Trust, F.S.B.	Fidelity Total Market Index Fund		13,433,953

See independent auditor's report.

**FUJIFILM Diosynth Biotechnologies
Long Term Savings Plan
Plan: 001 EIN: 45-1177477
Form 5500 Schedule H, Part IV, Line 4(i)
Schedule of Assets (Held at End of Year)
December 31, 2021**

(a)	(b)	(c)	(d)	(e)
	Identity of issue, borrower, lessor or similar party	Description of investment including maturity date, rate of interest collateral, par or maturity value	Cost**	Current Value
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2015		1,642,221
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2020		1,223,681
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2025		7,247,646
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2030		7,328,508
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2035		16,090,560
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2040		12,961,050
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2045		5,370,932
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2050		5,472,637
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2055		5,016,674
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2060		3,199,243
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement 2065		269,776
*	Prudential Bank & Trust, F.S.B.	Vanguard TGT Retirement Income		1,134,461
*	Prudential Bank & Trust, F.S.B.	Vanguard Total Intl Stock Index		7,312,116
				150,962,352
*	Notes receivable from participants	Interest rates ranging from 4.25% to 6.50%, various maturity dates, secured by participants' account balances	--	1,853,748
	Total			\$ 152,816,100

** Cost not required. (Investments are participant directed)

* Indicates an identified party known to be a party-in-interest to the Plan.